BUSINESS● LOWAug 25 · Aug 25, 2026, 9:01 PM
Spyre drops on disappointing phase 2 data for rheumatoid arthritis asset
Seeking Alpha Tech
Spyre's stock has declined following the release of disappointing Phase 2 clinical trial data for its rheumatoid arthritis treatment. This indicates a setback in the company's drug development efforts.
GlobeAlert aggregates and classifies open sources; the story above belongs to its publisher. Summaries are machine-generated from the source text.
More in Business
BUSINESS34m agoSouthwest to debut airport lounges in four cities, with more to comeCNBCBUSINESS38m agoSmall-cap bears were back. Was IWM the warning sign?Seeking Alpha TechBUSINESS44m agoTop 10 list: Forbes richest people in the world in 2026Vanguard NigeriaBUSINESS46m agoInvesting in STMicroelectronics: A Bet on Semiconductor InnovationYahoo Finance